SRAM
BMRN icon

Stone Ridge Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stone Ridge Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30,700
Closed -$2.74M – 1339
2017
Q4 		$2.74M Buy
+30,700
New +$2.67M 0.17% 111

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stone Ridge Asset Management's BMRN Position: Q1 2018 in Review

Stone Ridge Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 30,700 shares — an estimated $2.74M sold.

Stone Ridge Asset Management first reported a position in BMRN in Q4 2017 and held it in 1 quarter. The position peaked at $2.74M in Q4 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

  • Stone Ridge Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Stone Ridge Asset Management sold 30,700 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $2.74M.
  • Stone Ridge Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Stone Ridge Asset Management's BioMarin Pharmaceuticals position peaked at $2.74M in Q4 2017.
  • 429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Stone Ridge Asset Management's 13F filing for Q1 2018, filed 14 May 2018.